Skip to main content
OpenTrials
Completed

NCT Number: NCT04899830

Study of the Acceptability and Psychosocial Impact of Using a Telepresence Robot in the Living Space of Inpatients

This study focuses on the mobile robot assist device for tele-interaction: the "COVEALINK 2" robot. This telepresence robot is designed for remote use inside the home. It works with an Internet connection (Wifi or 4G). It consists of a control interface (an application installed on the smartphone or tablet of the hospitalized patient) and a mobile robot placed in the home of the hospitalized patient (composed of a mobile platform, a visualization screen whose tilt is adjustable remotely for better adaptation to the interlocutors and an audio communication system). From the app installed on his smartphone or tablet, the patient hospitalized in the center for a long time (2 months minimum) will be able to start remotely (from the center where he is hospitalized) the robot and have it move within his home to communicate with the people present at the time of use (family, friends, neighbors etc.).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CR Mulhouse, Mulhouse, Alsace, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≧ 18 years old
  • Affiliation to a social security scheme or beneficiary of such a scheme
  • Having signed a free informed consent in writing
  • Hospitalized in PRM for a foreseeable period of at least 60 days
  • Living space compatible with the movement of the robot (verified by a home visit by the center's occupational therapist) and equipped with wifi
  • Cognitive and motor functions compatible with the use of the tablet or phone independently, with learning capabilities to use the robot and the completion of questionnaires and interviews remotely
  • Medically stable

Exclusion criteria

  • Subject being in a period of exclusion from another protocol
  • Mood and behavior disorders not stabilized
  • Insufficient command of the French language
  • Protected adults (guardianship / curatorship)
  • Pregnant or breastfeeding women
  • Persons deprived of their liberty
  • Being unable to issue their consent
  • Person who has already presented a form of addiction to technologies and / or video games

Treatment and study plan

Telepresence robot

Device

From the application installed on a tablet, the patient hospitalized in a center for a period of at least 2 months can start from the center where he is hospitalized the mobile robotic telepresence assistance device installed at home to communicate with his family, his friends, his neighbors,…)

Primary outcomes

  1. Evaluation of the medium-term acceptance of robotic tele-interaction

    Time frame: At 2 months

    Measured with hospitalized patients using questionnaires developed by the LP3C (Laboratory of Psychology, Cognition, Behavior, Communication)

Secondary outcomes

  1. Evaluation of the a priori acceptability of robotic tele-interaction

    Time frame: Day 0

    Measured with hospitalized patients using questionnaires developed by the LP3C (Laboratory of Psychology, Cognition, Behavior, Communication). Measure of the a priori acceptability on Day 0. A priori acceptability corresponds to the study of representations of the user upstream of any use of the technology.

  2. Evaluation of the short-term acceptance of robotic tele-interaction

    Time frame: At 1 month

    Measured with hospitalized patients using questionnaires developed by the LP3C (Laboratory of Psychology, Cognition, Behavior, Communication). Measurement of acceptance at Day 30. The acceptance phase studies the user's judgment and impressions after the user's first interactions with the system

  3. Measure the effects of the use of the telepresence device on the patient's perception of his environment and his psycho-thymic state.

    Time frame: Day 0

    This assessment is done using validated measurement scale relating to depression and anxiety: HAD scale (Hospital Anxiety and Depression). The HAD scale is an instrument used to screen for anxiety and depressive disorders. It comprises 14 items graded from 0 to 3. Seven questions relate to anxiety (total A) and seven others to the depressive dimension (total D), thus making it possible to obtain two scores (maximum score for each score = 21 ).To screen for anxiety and depressive symptoms, the following interpretation is used for each of the scores (A and D): - 7 or less: no symptoms - 8 to 10: doubtful symptomatology - 11 and over: definite symptomatology.

  4. Measure the effects of the use of the telepresence device on the patient's perception of his environment and his psycho-thymic state.

    Time frame: Day 0

    This assessment is done using validated measurement scale relating to psychological well-being: EBEP (Psychological Well-Being Scale). The Ryff scale of psychological well-being "is constructed from six key dimensions: autonomy, mastery of the environment, personal development, positive relationships, giving meaning to one's life and acceptance of life. self. It consists of 18 items sides 1 to 6, where 6 indicating strongly agree. A high total score indicates psychological well-being.

  5. Measure the effects of the use of the telepresence device on the patient's perception of his environment and his psycho-thymic state.

    Time frame: Day 0

    This assessment is done using validated measurement scale relating to quality of life: questionnaire general SF-36 (Short Form 36 Healt Survey). The SF-36 questionnaire is a multidimensional questionnaire that assesses quality of life in relation to health status, regardless of causal pathology, gender, age and treatment. It assesses functioning and overall well-being using a questionnaire using 36 questions divided into 8 dimensions (physical functioning, role limitations related to physical health, physical pain, general health, vitality, functioning or social well-being, role limitations related to mental health, mental health).

  6. Measure the effects of the use of the telepresence device on the patient's perception of his environment and his psycho-thymic state.

    Time frame: Day 0

    This assessment is done using validated measurement scale relating to level of social participation: LHS scale (London Handicap Scale). This scale questions everyday life by assessing mobility, physical independence, occupation (work, hobbies, vacations, etc.), social integration, perception of the outside world and economic independence.

    It takes the form of a questionnaire comprising 6 items rated from 0 to 1: - 1 = no handicap - 0 = maximum handicap.

  7. Measure the effects of the use of the telepresence device on the patient's perception of his environment and his psycho-thymic state.

    Time frame: At 2 months

    This assessment is done using validated measurement scale relating to depression and anxiety: HAD scale (Hospital Anxiety and Depression). The HAD scale is an instrument used to screen for anxiety and depressive disorders. It comprises 14 items graded from 0 to 3. Seven questions relate to anxiety (total A) and seven others to the depressive dimension (total D), thus making it possible to obtain two scores (maximum score for each score = 21 ).To screen for anxiety and depressive symptoms, the following interpretation is used for each of the scores (A and D): - 7 or less: no symptoms - 8 to 10: doubtful symptomatology - 11 and over: definite symptomatology.

  8. Measure the effects of the use of the telepresence device on the patient's perception of his environment and his psycho-thymic state.

    Time frame: At 2 months

    This assessment is done using validated measurement scale relating to psychological well-being: EBEP (Psychological Well-Being Scale). The Ryff scale of psychological well-being "is constructed from six key dimensions: autonomy, mastery of the environment, personal development, positive relationships, giving meaning to one's life and acceptance of life. self. It consists of 18 items sides 1 to 6, where 6 indicating strongly agree. A high total score indicates psychological well-being.

  9. Measure the effects of the use of the telepresence device on the patient's perception of his environment and his psycho-thymic state.

    Time frame: At 2 months

    This assessment is done using validated measurement scale relating to quality of life: questionnaire general SF-36 (Short Form 36 Healt Survey). The SF-36 questionnaire is a multidimensional questionnaire that assesses quality of life in relation to health status, regardless of causal pathology, gender, age and treatment. It assesses functioning and overall well-being using a questionnaire using 36 questions divided into 8 dimensions (physical functioning, role limitations related to physical health, physical pain, general health, vitality, functioning or social well-being, role limitations related to mental health, mental health).

  10. Measure the effects of the use of the telepresence device on the patient's perception of his environment and his psycho-thymic state.

    Time frame: At 2 months

    This assessment is done using validated measurement scale relating to level of social participation: LHS scale (London Handicap Scale). This scale questions everyday life by assessing mobility, physical independence, occupation (work, hobbies, vacations, etc.), social integration, perception of the outside world and economic independence.

    It takes the form of a questionnaire comprising 6 items rated from 0 to 1: - 1 = no handicap - 0 = maximum handicap.

  11. Evaluation of the a priori acceptability of robotic tele-interaction for users, relatives and members of the multidisciplinary team

    Time frame: Day 0

    Measurement with categories of users around the patient and members of the multidisciplinary team, using questionnaires developed by the LP3C (Laboratory of Psychology, Cognition, Behavior, Communication). Measurement of a priori acceptability on Day 0. A priori acceptability corresponds to the study of representations of the user upstream of any use of the technology.

  12. Evaluation of the medium-term acceptance of robotic tele-interaction for users, relatives and members of the multidisciplinary team

    Time frame: At 2 months

    Measurement with categories of users around the patient and members of the multidisciplinary team, using questionnaires developed by the LP3C (Laboratory of Psychology, Cognition, Behavior, Communication). Measurement of acceptance at Day 60. The acceptance phase studies the user's judgment and impressions after the user's first interactions with the system.

Sponsors and collaborators

Lead sponsor

Association APPROCHE

Other

Collaborators

  • COVEA
  • University of Rennes 2

Registry information

Acronym: ROBOLINK-e

Important dates

Study start
2020
Primary completion
2024
Study completion
2024
First posted
May 25, 2021
Registry last updated
Mar 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.